Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 28

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 28
---
ization among our prior peer group.

The compensation study prepared by Compensia and presented in October 2023 provided an assessment of our compensation practices as compared to industry peers. Compensation levels for our executive officers, in the aggregate, were determined to be within the range of compensation provided to similarly placed executives and consistent with our compensation philosophy.

#### Individual Compensation Elements
In 2024, the principal elements of our executive compensation program were as follows:

• base salary;

• an annual cash incentive compensation opportunity;

• long-term incentive compensation in the form of equity awards;

• welfare and health benefits; and

• post-employment compensation arrangements.

Base Salary

Base salary represents the fixed portion of the compensation of our executive officers, including our NEOs, and is an important element of compensation intended to attract and retain highly-talented individuals.

The initial base salaries for our executive officers were negotiated on an individual basis at the time of hire. Thereafter, using the competitive market data provided by its external compensation consultant, the Compensation Committee reviews and determines adjustments to the base salaries for each of our executive officers, including our NEOs, as part of its annual executive compensation review. In addition, the base salaries of our executive officers may be adjusted by the Compensation Committee in the event of a promotion or significant change in responsibilities. Generally, the Compensation Committee sets base salaries with reference to the competitive range of the market median of our compensation peer group and applicable executive compensation survey data, as well as its assessment of the factors described in “Governance of Executive Compensation Program - Compensation-Setting Process” above.

The base salaries of our NEOs for fiscal 2024 and fiscal 2023 were as follows:

| Named Executive                               
 Officer                                       |     | Fiscal 2024Base Salary |     | Fiscal 2023 Base Salary |     | Percentage 
 Adjustment |
| Christopher Anzalone                          
 President & CEO                               |     |               $960,000 |     |                $913,868 |     | 5%         |
| Kenneth Myszkowski                            
 Chief Financial Officer                       |     |               $582,400 |     |                $560,000 |     | 4%         |
| Patrick O’Brien                               
 Chief Operating Officer andGeneral Counsel    |     |               $600,000 |     |                $560,000 |     | 7%         |
| James Hamilton                                
 Chief of Discovery and Translational Medicine |     |               $582,400 |     |                $525,000 |     | 11%        |